Target intelligence / Profile preview

Tripartite motif-containing protein 3 (TRIM3)

Target
TRIM3
Molecular classification
E3 ubiquitin ligase, RING finger protein, Tripartite motif family (TRIM-NHL protein family), Other
01

Overview

Tripartite motif-containing protein 3 (TRIM3) is a cytoplasmic E3 ubiquitin ligase belonging to the TRIM-NHL protein family and characterized by a RING finger, two B-box domains, and a coiled-coil region[3][5]. TRIM3 acts as a tumor suppressor and is the human ortholog of the Drosophila 'brain tumor' (brat) protein[4]. It is involved in ubiquitination and degradation or stabilization of various substrate proteins, impacting cell cycle progression, growth suppression, and apoptosis regulation[2][3][4]. TRIM3 targets and ubiquitinates proteins such as P53, Estrogen receptor alpha, SLC7A11, and LDHA, thereby regulating tumorigenesis and metabolic adaptation in cancer cells[3][4]. Loss of TRIM3 expression is associated with increased cell proliferation, cancer stem cell phenotypes, resistance to apoptosis, and poor prognosis in several human cancers[4]. Additionally, TRIM3 may play a role in intracellular cargo transport via interaction with myosin V and alpha-actinin-4, and its domain structure allows complex regulation and protein-protein interactions typical of the diversified TRIM protein family[3][5][1].

Other names
BERPHAC1RNF22RNF97Brain-expressed RING finger proteinRING finger protein 22RING finger protein 97brain expressed ring fingertripartite motif protein TRIM3
02

Mechanism of action

Targeted protein ubiquitination (E3 ligase activity), Ubiquitination and degradation of specific substrates (e.g., P53, Estrogen receptor alpha, SLC7A11, lactate dehydrogenase A), Stabilization of target proteins via non-proteolytic ubiquitination

03

Biological functions

Protein ubiquitinationTumor suppressionCell cycle regulationAsymmetric cell divisionCargo transport (myosin V-mediated)Regulation of signaling pathways (e.g., PI3K/AKT, p38)Regulation of apoptosisModulation of cellular metabolism (glycolysis/ferroptosis)
04

Disease associations

Cancer (notably glioblastoma, hepatocellular carcinoma, colorectal, gastric, ovarian, cervical, and non-small cell lung cancers)Neurodegenerative disease (suggested, due to role in brain and interaction with cytoskeletal proteins)Other
05

Safety considerations

TRIM family redundancy and functional overlap complicate therapeutic targetingpotential off-target effects due to family-wide modulationessential cellular roles in protein turnover
06

Biomarkers

Potential biomarker for tumor suppression (expression loss correlates with poor outcomes in certain cancers)Not yet established for routine clinical use

Beyond the preview

Go deeper on Tripartite motif-containing protein 3 (TRIM3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tripartite motif-containing protein 3 (TRIM3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call